Overview
Annovis Bio has raised $10 million in an underwritten public offering to extend its cash runway into Q2 2027, supporting its Alzheimer's phase 3 trial and the first NDA submission for its drug, Buntanetap. The trial is 75% enrolled, with key data expected in Q1 2027. The funding also includes a recent $1.5 million investment from board chair Michael Hoffman, and the FDA has agreed to streamline the regulatory process by including safety data from both Alzheimer's and Parkinson's programs.
Products
Loading...
Recent Deals
Investors: Michael Hoffman
Annovis Bio has raised $10 million in an underwritten public offering to extend its cash runway into Q2 2027, supporting its Alzheimer's phase 3 trial and the first NDA submission for its drug, Buntanetap. The trial is 75% enrolled, with key data expected in Q1 2027. The funding also includes a recent $1.5 million investment from board chair Michael Hoffman, and the FDA has agreed to streamline the regulatory process by including safety data from both Alzheimer's and Parkinson's programs.